O	0	6	Effect
O	7	9	of
B-intervention	10	17	Aerobic
I-intervention	18	21	and
I-intervention	22	32	Resistance
I-intervention	33	41	Exercise
O	42	54	Intervention
O	55	57	on
B-condition	58	72	Cardiovascular
I-condition	73	80	Disease
I-condition	81	85	Risk
O	86	88	in
B-eligibility	89	94	Women
I-eligibility	95	99	With
I-eligibility	100	105	Early
I-eligibility	105	106	-
I-eligibility	106	111	Stage
I-eligibility	112	118	Breast
I-eligibility	119	125	Cancer
O	125	126	:
O	127	128	A
O	129	139	Randomized
O	140	148	Clinical
O	149	154	Trial
O	154	155	.

O	156	159	The
O	160	170	Framingham
O	171	175	Risk
O	176	181	Score
O	182	183	(
O	183	186	FRS
O	186	187	)
O	188	190	is
O	191	192	a
O	193	198	valid
O	199	205	method
O	206	209	for
O	210	220	predicting
O	221	224	the
O	225	227	10
O	227	228	-
O	228	232	year
O	233	237	risk
O	238	240	of
O	241	251	developing
O	252	266	cardiovascular
O	267	274	disease
O	274	275	.

O	276	282	Higher
O	283	286	FRS
O	287	289	is
O	290	298	reported
O	299	301	in
O	302	310	patients
O	311	315	with
O	316	321	early
O	321	322	-
O	322	327	stage
O	328	334	breast
O	335	341	cancer
O	342	345	who
O	346	349	are
O	350	360	overweight
O	361	365	than
O	366	368	in
O	369	376	healthy
O	376	377	,
O	378	381	age
O	381	382	-
O	382	389	matched
O	390	395	women
O	395	396	,
O	397	400	but
O	401	408	whether
O	409	417	exercise
O	418	425	reduces
O	426	429	FRS
O	430	432	in
O	433	437	this
O	438	445	patient
O	446	456	population
O	457	459	is
O	460	467	unclear
O	467	468	.

O	469	471	To
O	472	479	examine
O	480	483	the
O	484	491	effects
O	492	494	of
O	495	496	a
B-eligibility	497	499	16
I-eligibility	499	500	-
I-eligibility	500	504	week
O	505	512	aerobic
O	513	516	and
O	517	527	resistance
O	528	536	exercise
O	537	549	intervention
O	550	552	on
O	553	556	the
O	557	560	FRS
O	561	563	in
O	564	569	women
O	570	574	with
O	575	580	early
O	580	581	-
O	581	586	stage
O	587	593	breast
O	594	600	cancer
O	601	604	and
O	605	609	with
O	610	620	overweight
O	621	630	condition
O	631	633	or
O	634	641	obesity
O	641	642	.

O	643	647	This
O	648	654	single
O	654	655	-
O	655	661	center
O	661	662	,
O	663	674	prospective
O	675	685	randomized
O	686	694	clinical
O	695	700	trial
O	701	709	included
B-total-participants	710	713	100
B-eligibility	714	719	women
I-eligibility	720	724	with
I-eligibility	725	730	stage
I-eligibility	731	732	I
I-eligibility	733	735	to
I-eligibility	736	739	III
I-eligibility	740	746	breast
I-eligibility	747	753	cancer
I-eligibility	754	757	who
I-eligibility	758	762	were
I-eligibility	763	772	sedentary
I-eligibility	772	773	,
I-eligibility	774	778	with
I-eligibility	779	789	overweight
I-eligibility	790	799	condition
I-eligibility	800	802	or
I-eligibility	803	810	obesity
I-eligibility	811	812	(
I-eligibility	812	816	body
I-eligibility	817	821	mass
I-eligibility	822	827	index
I-eligibility	828	830	of
I-eligibility	831	832	≥
I-eligibility	832	834	25
I-eligibility	834	835	.
I-eligibility	835	836	0
I-eligibility	837	839	or
I-eligibility	840	844	body
I-eligibility	845	848	fat
I-eligibility	849	851	of
I-eligibility	852	853	≥
I-eligibility	853	855	30
I-eligibility	855	856	%
I-eligibility	856	857	)
I-eligibility	857	858	,
I-eligibility	859	862	and
I-eligibility	863	872	completed
I-eligibility	873	879	cancer
I-eligibility	880	889	treatment
I-eligibility	890	896	within
I-eligibility	897	898	6
I-eligibility	899	905	months
I-eligibility	906	911	prior
I-eligibility	912	914	to
I-eligibility	915	925	enrollment
O	925	926	.

O	927	939	Participants
O	940	944	were
O	945	955	randomized
O	956	958	to
O	959	965	either
O	966	969	the
B-control	970	975	usual
I-control	976	980	care
O	981	983	or
O	984	992	exercise
O	993	998	group
O	998	999	.

O	1000	1011	Differences
O	1012	1014	in
O	1015	1019	mean
O	1020	1027	changes
O	1028	1031	for
O	1032	1040	outcomes
O	1041	1045	were
O	1046	1055	evaluated
O	1056	1061	using
O	1062	1067	mixed
O	1067	1068	-
O	1068	1073	model
O	1074	1082	repeated
O	1082	1083	-
O	1083	1091	measures
O	1092	1100	analyses
O	1100	1101	.

O	1102	1106	Data
O	1107	1111	were
O	1112	1121	collected
O	1122	1126	from
O	1127	1133	August
O	1134	1135	1
O	1135	1136	,
O	1137	1141	2012
O	1141	1142	,
O	1143	1150	through
O	1151	1155	July
O	1156	1157	1
O	1157	1158	,
O	1159	1163	2017
O	1163	1164	.

O	1165	1169	Data
O	1170	1178	analysis
O	1178	1179	,
O	1180	1185	which
O	1186	1194	followed
O	1195	1198	the
O	1199	1208	intention
O	1208	1209	-
O	1209	1211	to
O	1211	1212	-
O	1212	1217	treat
O	1218	1226	approach
O	1226	1227	,
O	1228	1231	was
O	1232	1241	performed
O	1242	1246	from
O	1247	1250	May
O	1251	1253	24
O	1254	1256	to
O	1257	1264	October
O	1265	1266	2
O	1266	1267	,
O	1268	1272	2018
O	1272	1273	.

O	1274	1277	The
O	1278	1286	exercise
O	1287	1292	group
O	1293	1302	underwent
O	1303	1313	supervised
O	1314	1321	aerobic
O	1322	1325	and
O	1326	1336	resistance
O	1337	1345	exercise
O	1346	1354	sessions
O	1355	1361	thrice
O	1362	1368	weekly
O	1369	1372	for
O	1373	1375	16
O	1376	1381	weeks
O	1381	1382	.

O	1383	1386	The
O	1387	1390	FRS
O	1391	1394	was
O	1395	1405	calculated
O	1406	1409	for
O	1410	1414	each
O	1415	1426	participant
O	1427	1432	using
O	1433	1439	preset
O	1440	1446	points
O	1447	1450	for
O	1451	1455	each
O	1456	1458	of
O	1459	1462	the
O	1463	1464	6
O	1465	1468	FRS
O	1469	1479	categories
O	1479	1480	:
O	1481	1484	age
O	1484	1485	,
O	1486	1494	systolic
O	1495	1500	blood
O	1501	1509	pressure
O	1509	1510	,
O	1511	1515	high
O	1515	1516	-
O	1516	1523	density
O	1524	1535	lipoprotein
O	1536	1547	cholesterol
O	1547	1548	,
O	1549	1552	low
O	1552	1553	-
O	1553	1560	density
O	1561	1572	lipoprotein
O	1573	1584	cholesterol
O	1584	1585	,
O	1586	1594	diabetes
O	1595	1603	presence
O	1603	1604	,
O	1605	1608	and
O	1609	1616	smoking
O	1617	1623	status
O	1623	1624	.

O	1625	1627	In
O	1628	1633	total
O	1633	1634	,
B-total-participants	1635	1638	100
O	1639	1644	women
O	1645	1649	were
O	1650	1660	randomized
O	1661	1663	to
O	1664	1670	either
O	1671	1674	the
O	1675	1683	exercise
O	1684	1689	group
O	1690	1691	(
O	1691	1692	n
O	1693	1694	=
B-intervention-participants	1695	1697	50
O	1697	1698	)
O	1699	1701	or
O	1702	1707	usual
O	1708	1712	care
O	1713	1718	group
O	1719	1720	(
O	1720	1721	n
O	1722	1723	=
B-control-participants	1724	1726	50
O	1726	1727	)
O	1727	1728	.

O	1729	1731	Of
O	1732	1737	these
O	1738	1743	women
O	1743	1744	,
O	1745	1747	55
O	1748	1749	(
O	1749	1751	55
O	1751	1752	%
O	1752	1753	)
O	1754	1758	were
O	1759	1761	of
B-ethinicity	1762	1770	Hispanic
I-ethinicity	1771	1776	white
O	1777	1781	race
O	1781	1782	/
O	1782	1791	ethnicity
O	1792	1795	and
O	1796	1799	the
O	1800	1804	mean
O	1805	1806	(
O	1806	1808	SD
O	1808	1809	)
O	1810	1813	age
O	1814	1817	was
B-age	1818	1820	53
I-age	1820	1821	.
I-age	1821	1822	5
I-age	1823	1824	(
I-age	1824	1826	10
I-age	1826	1827	.
I-age	1827	1828	4
I-age	1828	1829	)
I-age	1830	1835	years
O	1835	1836	.

O	1837	1840	The
B-outcome	1841	1845	mean
I-outcome	1846	1847	(
I-outcome	1847	1849	SD
I-outcome	1849	1850	)
I-outcome	1851	1856	total
I-outcome	1857	1860	FRS
I-outcome	1861	1867	scores
O	1868	1884	postintervention
O	1885	1889	were
B-iv-cont-mean	1890	1891	2
I-iv-cont-mean	1891	1892	.
I-iv-cont-mean	1892	1893	0
O	1894	1895	(
B-iv-cont-sd	1895	1896	1
I-iv-cont-sd	1896	1897	.
I-iv-cont-sd	1897	1898	5
O	1898	1899	)
O	1900	1902	in
O	1903	1906	the
O	1907	1915	exercise
O	1916	1921	group
O	1922	1925	and
B-cv-cont-mean	1926	1928	13
I-cv-cont-mean	1928	1929	.
I-cv-cont-mean	1929	1930	0
O	1931	1932	(
B-cv-cont-sd	1932	1933	3
I-cv-cont-sd	1933	1934	.
I-cv-cont-sd	1934	1935	0
O	1935	1936	)
O	1937	1939	in
O	1940	1943	the
O	1944	1949	usual
O	1950	1954	care
O	1955	1960	group
O	1960	1961	.

O	1962	1965	The
B-outcome	1966	1982	postintervention
I-outcome	1983	1986	FRS
O	1987	1990	was
O	1991	2004	significantly
O	2005	2012	reduced
O	2013	2015	in
O	2016	2019	the
O	2020	2028	exercise
O	2029	2034	group
O	2035	2043	compared
O	2044	2048	with
O	2049	2052	the
O	2053	2058	usual
O	2059	2063	care
O	2064	2069	group
O	2070	2071	(
O	2071	2075	mean
O	2075	2076	,
O	2077	2078	-
O	2078	2079	9
O	2079	2080	.
O	2080	2081	5
O	2081	2082	;
O	2083	2085	95
O	2085	2086	%
O	2087	2089	CI
O	2089	2090	,
O	2091	2092	-
O	2092	2094	13
O	2094	2095	.
O	2095	2096	0
O	2097	2099	to
O	2100	2101	-
O	2101	2102	6
O	2102	2103	.
O	2103	2104	0
O	2104	2105	)
O	2105	2106	,
O	2107	2112	which
O	2113	2124	corresponds
O	2125	2127	to
O	2128	2130	an
O	2131	2133	11
O	2133	2134	%
O	2135	2136	(
O	2136	2138	95
O	2138	2139	%
O	2140	2142	CI
O	2142	2143	,
O	2144	2145	-
O	2145	2147	15
O	2147	2148	.
O	2148	2149	0
O	2150	2152	to
O	2153	2154	-
O	2154	2155	5
O	2155	2156	.
O	2156	2157	0
O	2157	2158	)
O	2159	2167	decrease
O	2168	2170	on
O	2171	2174	the
O	2175	2178	FRS
O	2178	2179	-
O	2179	2188	predicted
O	2189	2191	10
O	2191	2192	-
O	2192	2196	year
O	2197	2201	risk
O	2202	2204	of
O	2205	2215	developing
O	2216	2230	cardiovascular
O	2231	2238	disease
O	2238	2239	.

O	2240	2241	A
O	2242	2244	16
O	2244	2245	-
O	2245	2249	week
O	2250	2260	supervised
O	2261	2268	aerobic
O	2269	2272	and
O	2273	2283	resistance
O	2284	2292	exercise
O	2293	2305	intervention
O	2306	2314	appeared
O	2315	2317	to
O	2318	2324	reduce
O	2325	2328	the
O	2329	2332	FRS
O	2332	2333	-
O	2333	2342	predicted
O	2343	2345	10
O	2345	2346	-
O	2346	2350	year
O	2351	2355	risk
O	2356	2358	of
O	2359	2373	cardiovascular
O	2374	2381	disease
O	2382	2384	in
O	2385	2390	women
O	2391	2395	with
O	2396	2401	early
O	2401	2402	-
O	2402	2407	stage
O	2408	2414	breast
O	2415	2421	cancer
O	2422	2426	with
O	2427	2437	overweight
O	2438	2447	condition
O	2448	2450	or
O	2451	2458	obesity
O	2458	2459	.

O	2460	2474	ClinicalTrials
O	2474	2475	.
O	2475	2478	gov
O	2479	2489	identifier
O	2489	2490	:
O	2491	2502	NCT01140282
O	2502	2503	.
